SEQUENCE LISTING

<110> Findell, Paul R.
Marinkovich, III, M. Peter

<120> METHODS OF AFFECTING LAMININ 5 PROCESSING

<130> FG0911-US

<140>
<141>

<150> 60/203,708
<151> 2000-05-12

<160> 9

<170> PatentIn Ver. 2.0

<210> 1
<211> 8
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: human peptide

<400> 1
Cys Tyr Ser Gly Asp Glu Asn Pro
1 5

<210> 2
<211> 8
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: human peptide

<400> 2
Leu Gln Phe Gly Asp Ile Pro Thr
1 5

<210> 3
<211> 9
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: human peptide

<400> 3
Gln Leu Leu Gln Asp Thr Pro Val Ala
1 5

<210> 4
<211> 8
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: human peptide

<400> 4
Lys Val Trp Gln Asp Ala Cys Ser
1 5

<210> 5
<211> 8
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: human peptide

<400> 5
Gln Phe Ala Val Asp Met Gln Thr
1 5

<210> 6
<211> 14
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: human peptide

<400> 6
Asn Cys Glu His Gly Ala Phe Ser Cys Pro Ala Cys Tyr Asn
1 5 10

<210> 7
<211> 14
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: rat peptide

<400> 7

Arg Thr Ala Ala Ala Leu Thr Ser Cys Pro Ala Cys Tyr Asn
1 5 10

<210> 8
<211> 14
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: human peptide

<400> 8
Gly Asp Cys Tyr Ser Gly Asp Glu Asn Pro Asp Thr Glu Cys
1 5 10

<210> 9
<211> 14
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: human peptide

<400> 9
Gly Ala Leu Gln Phe Gly Asp Ile Pro Thr Ser His Leu Leu
1 5 10